Astilbin protects diabetic rat heart against ischemia-reperfusion injury via blockade of HMGB1-dependent NF-κB signaling pathway

Food and Chemical Toxicology

Volumn 63, Issue , 2014, Pages 104-110

  Diao, Huiling ^a   Kang, ZeChun ^a   Han, Fang ^a   Jiang, WangLin ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Astilbin; Diabetes mellitus; High mobility group box 1 protein; Myocardial ischemia and reperfusion; Nuclear factor kappaB

Indexed keywords

ASTILBIN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ADULT ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EXPERIMENTAL DIABETES MELLITUS; HEART DISEASE; HEART HEMODYNAMICS; HEART INFARCTION SIZE; HEART INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART REMODELING; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

RATTUS; SMILAX CHINA;

ASTILBIN; DIABETES MELLITUS; HIGH MOBILITY GROUP BOX-1 PROTEIN; MYOCARDIAL ISCHEMIA AND REPERFUSION; NUCLEAR FACTOR KAPPAB;

ANIMALS; BLOTTING, WESTERN; DIABETES MELLITUS, EXPERIMENTAL; FLAVONOLS; HEART; HMGB1 PROTEIN; INFLAMMATION MEDIATORS; MALE; MYOCARDIAL REPERFUSION INJURY; NF-KAPPA B; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 84888244071     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2013.10.045     Document Type: Article

References (29)

1. Alcorn T., Ouyang Y. Diabetes saps health and wealth from China's rise. Lancet 2012, 379:2227-2228.
2. Andrassy M., Volz H.C., Bianchi M.E., Kaya Z. The role of HMGB1 in the development of diabetic cardiomyopathy. Circulation 2008, 118:S351-S352.
3. Andrassy M., Volz H.C., Igwe J.C., Funke B., Eichberger S.N., Kaya Z. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008, 117:3216-3226.
4. Bolli R., Becker L., Gross G., Mentzer R.J., Balshaw D., Lathrop D.A. NHLBI working group on the translation of therapies for protecting the heart from ischemia. Myocardial protection at a crossroads, the need for translation into clinical therapy. Circ. Res. 2004, 95:125.
5. Cai Y., Chen T., Xu Q. Astilbin suppresses collagen-induced arthritis via the dysfunction of lymphocytes. Inflamm. Res. 2003, 52:334-340.
6. Chen L., Lan Z., Zhou Y., Li F., Zhang X., Zhang C. Astilbin attenuates hyperuricemia and ameliorates nephropathy in fructose-induced hyperuricemic rats. Plant. Med. 2011, 77:1769-1773.
7. Chen Y., Wang Q., Li B., Li L., Pan L.N., Huang Y. Study on identification and quality for Smilax china L. of compound gout granules. Asia-Pacific Tradit. Med. 2008, 4:237-239.
8. Di Filippo C., Marfella R., Cuzzocrea S., Piegari E., Petronella P., Giugliano D., Rossi F., D'Amico M. Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ischemia/reperfusion. Diabetes 2005, 54:803-810.
9. Fishbein M.C., Maclean D., Maroko P.R. Experimental myocardial infarction in the rat, qualitative and quantitative changes during pathologic evolution. Am. J. Pathol. 1978, 90:57-70.
10. Fiuza C., Bustin M., Talwar S., Tropea M., Gerstenberger E., Shelhamer J.H. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003, 101:2652-2660.
11. Frantz S., Tillmanns J., Kuhlencordt P.J., Schmidt I., Adamek A., Dienesch C. Tissue-specific effects of the NF-κB subunit p50 on myocardial ischemia-reperfusion injury. Am. J. Pathol. 2007, 171:507-512.
12. Hanefeld M., Duetting E., Bramlage P. Cardiac implications of hypoglycaemia in patients with diabetes-a systematic review. Cardiovasc. Diabetol. 2013, 12:135.
13. Jiang W.L., Fu F.H., Xu B.M., Tian J.W., Zhu H.B., Hou J. Cardioprotection with forsythoside B in rat myocardial ischemia-reperfusion injury: relation to inflammation response. Phytomedicine 2010, 17:635-639.
14. Jiang W.L., Zhang S.P., Zhu H.B., Hou J. Cardioprotection of Asperosaponin X on experimental myocardial ischemia injury. Int. J. Cardiol. 2012, 155:430-436.
15. Kawano S., Kubota T., Monden Y., Tsutsumi T., Inoue T., Kawamura N. Blockade of NF-kappaB improves cardiac function and survival after myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2006, 291. H1337-1344.
16. Kim J.W., Jin Y.C., Kim Y.M., Rhie S., Kim H.J., Seo H.G. Daidzein administration in vivo reduces myocardial injury in a rat ischemia/reperfusion model by inhibiting NF-κB activation. Life Sci. 2009, 84:227-234.
17. Kuusisto J., Laakso M. Update on type 2 diabetes as a cardiovascular disease risk equivalent. Curr. Cardiol. Rep. 2013, 15:331.
18. Li G.S., Jiang W.L., Yue X.D., Qu G.W., Tian J.W., Wu J. Effect of Astilbin on experimental diabetic nephropathy in vivo and in vitro. Plant. Med. 2009, 75:1470-1475.
19. Lotze M.T., Tracey K.J. High-mobility group box 1protein (HMGB1), nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 2005, 5:331-342.
20. Loukili N., Rosenblatt-Velin N., Li J., Clerc S., Pacher P., Feihl F. Peroxynitrite induces HMGB1 release by cardiac cells in vitro and HMGB1 upregulation in the infarcted myocardium in vivo. Cardiovasc. Res. 2011, 89:586-594.
21. Mair J., Artner-Dworzak E., Lechleitner P., Smidt J., Wagner I., Dienstl F. Cardiac troponin T in diagnosis of acute myocardial infarction. Clin. Chem. 1991, 37:845-852.
22. Małek R., Borowicz K.K., Jargiełło M., Czuczwar S.J. Role of NF-κB in the central nervous system. Pharmacol. Rep. 2007, 59:25-33.
23. Penzo M., Molteni R., Suda T., Samaniego S., Raucci A., Habiel D.M. Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis. J. Immunol. 2010, 184:4497-4509.
24. Volz H.C., Seidel C., Laohachewin D., Kaya Z., Müller O.J., Pleger S.T. HMGB1: the missing link between diabetes mellitus and heart failure. Basic Res. Cardiol. 2010, 105:805-820.
25. Waddick K.G., Uckun F.M. Innovative treatment programs against cancer, II nuclear factor-kappa B as a molecular target. Biochem. Pharmacol. 1999, 57:9-17.
26. Wang J., Zhao Y., Xu Q. Astilbin prevents concanavalin A-induced liver injury by reducing TNF-α production and T lymphocytes adhesion. J. Pharm. Pharmacol. 2004, 56(495-502):5.
27. Wu A.H., Lane P.L. Metaanalysis in clinical chemistry, validation of cardiac troponin T as a marker for ischemic heart diseases. Clin. Chem. 1995, 41:1228-1233.
28. Yang J., Huang C., Yang J., Jiang H., Ding J. Statins attenuate high mobility group box-1 protein induced vascular endothelial activation, a key role for TLR4/NF-κB signaling pathway. Mol. Cell. Biochem. 2010, 345:189-195.
29. Zhu J., Qiu Y., Wang Q., Zhu Y., Hu S., Zheng L. Low dose cyclophosphamide rescues myocardial function from ischemia-reperfusion in rats. Eur. J. Cardiothorac. Surg. 2008, 34:661-666.